Late Breaking Abstract - Sustained FEV1 improvements with mepolizumab up to 104 weeks in patients with COPD and less severe airflow obstruction: Post hoc analysis of the MATINEE Phase III study

Category Primary study
ConferenceEuropean Respiratory Society Congress, ERS 2025
Year 2025
This article has no abstract
Epistemonikos ID: 232f53fd53b080a3aa8eaa1cccf42eff3fa20206
First added on: Apr 18, 2026